Based on the results of this retrospective analysis, methotrexate weekly as single agent or in combination with gefitinib appears as an attractive alternative regimen for patients with metastatic HNSCC including those having poor performance status. A prospective study was planned and submitted to the local ethics committee based on above results to validate these results and compare methotrexate and gefitinib arm with 5-FU + cisplatin.
via Palliative chemotherapy in head and neck squamous cell cancer – What is best in Indian population? A time without symptoms, treatment toxicity score based study Anuradha V, Anand B B, Suresh A, Sinha S, Babu S C, Suresh K – Indian J Med Paediatr Oncol.